Related Experiment Video
Updated: Jun 25, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Serum IgA as a Prognostic Beacon: Anticipating Systemic Therapy Efficacy in Metastatic Clear Cell Renal Cell
Hong-Lei Cui1, Jie Wu1, Gan Du1
1Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Chinese Academy of Medical Sciences, Peking Union Medical College Cancer Hospital, Beijing, China.
Objective:
Immunotherapy-tyrosine kinase inhibitor (IO-TKI) therapy has revolutionized the treatment landscape for metastatic clear cell renal cell carcinoma (mccRCC); however, the absence of effective biomarkers poses a challenge in predicting the efficacy of these regimens. This study aims to explore the predictive and prognostic value of serum immunoglobulin A (IgA) in mccRCC patients undergoing IO-TKI therapy.
Methods:
Ninety-six mccRCC patients treated with IO-TKI therapy from 2019 to 2023 were enrolled and serum IgA levels were assessed at the pretreatment baseline and after 3 months of treatment.
Results:
Notably, baseline levels of IgA showed no correlation with the objective response rate. However, patients achieving complete or partial responses exhibited a remarkable decrease in IgA levels, while those with stable or progressive disease displayed an increase in IgA levels after 3 months of treatment. Furthermore, the dynamic alteration in IgA levels after 3 months of treatment demonstrated predictive value for both progression-free survival (PFS) and overall survival (OS). The time-dependent receiver operating characteristic curves exhibited outstanding performance in predicting PFS (AUC 0.793) and OS (AUC 0.738).
Conclusion:
Taken together, this study demonstrates that dynamic alteration of serum IgA after 3 months of treatment was significantly correlated with prognosis and therapeutic efficacy in mccRCC patients.
Insights
Serum immunoglobulin A (IgA) levels dynamically change with treatment response in metastatic clear cell renal cell carcinoma (mccRCC) patients. This alteration predicts progression-free survival and overall survival in patients receiving immunotherapy-tyrosine kinase inhibitor (IO-TKI) therapy.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Metastatic clear cell renal cell carcinoma (mccRCC) treatment has advanced with immunotherapy-tyrosine kinase inhibitor (IO-TKI) therapy.
- Predictive biomarkers for IO-TKI efficacy in mccRCC are currently lacking, posing a clinical challenge.
Discussion:
- This study investigated the predictive and prognostic significance of serum immunoglobulin A (IgA) in mccRCC patients undergoing IO-TKI therapy.
- Serum IgA levels were assessed at baseline and after three months of IO-TKI treatment in 96 mccRCC patients.
- Baseline IgA levels did not correlate with objective response rates.
Key Insights:
- A decrease in serum IgA levels after three months of IO-TKI treatment was observed in patients with complete or partial responses.
- An increase in serum IgA levels was noted in patients with stable or progressive disease.
- Dynamic changes in serum IgA levels after three months demonstrated significant predictive value for progression-free survival (PFS) and overall survival (OS).
Outlook:
- The study highlights the potential of dynamic serum IgA alterations as a prognostic biomarker in mccRCC.
- Further research may validate serum IgA as a tool to personalize IO-TKI treatment strategies for mccRCC patients.
- Serum IgA monitoring could aid in early prediction of treatment response and patient outcomes.
